NanoCor Therapeutics Inc., a Chapel Hill, N.C.-based developer of an intracellular genetic protein therapy for the treatment of chronic heart failure, has raised $3.75 million in Series B funding from Medtronic. The deal also includes a second $3.75 million tranche, payable when NanoCor achieves certain milestones. NanoCor was launched in August 2005 as a spinout from Asklepios Biopharmaceutical Inc. www.nanocorthx.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.